Published online Jul 21, 2025. doi: 10.3748/wjg.v31.i27.109239
Revised: May 28, 2025
Accepted: June 16, 2025
Published online: July 21, 2025
Processing time: 78 Days and 7.8 Hours
Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), are chronic gastrointestinal disorders with an increasing global prevalence and significant healthcare impact. The exact etiology of this condition remains unclear. Neutrophils play a critical role in IBD pathogenesis. Translocator protein (TSPO), a mitochondrial protein linked to immune responses, has demon
To investigate the role of TSPO in IBD pathogenesis, particularly in neutrophils.
Bioinformatics analyses of Gene Expression Omnibus datasets (GE75214, GSE94648, GSE156776) assessed TSPO expression in IBD patients. TSPO expre
Bioinformatics analysis revealed elevated TSPO expression in the intestinal mucosa and peripheral blood of patients with IBD, especially in neutrophils. This was confirmed by quantitative real-time polymerase chain reaction and immunohistochemical staining, which showed a significant upregulation of TSPO in active IBD. Neutrophils from patients with UC and CD exhibited higher TSPO expression, which correlated with increased ROS production and NET formation. In a mouse model of dextran sodium sulfate-induced chronic colitis, TSPO was upregulated in the colonic neutrophils and brain tissues, indicating its systemic involvement. PET-CT imaging showed enhanced TSPO uptake in the inflamed colon and brain regions, particularly in the microglia, highlighting neuroinflammation.
TSPO is significantly upregulated in neutrophils in IBD and contributes to intestinal inflammation. Its elevated expression in gut highlights its potential as a promising therapeutic target for IBD.
Core Tip: This research recognizes translocator protein (TSPO) as a novel biomarker and promising therapeutic target for inflammatory bowel diseases (IBD). Elevated TSPO expression was observed in neutrophils of IBD patients, along with increased reactive oxygen species production and neutrophil extracellular trap formation. Additionally, upregulated TSPO in both the inflamed colon and brain tissue suggests its contributions to autoimmune inflammation and neuroinflammation. These findings recommend TSPO as a potential target for IBD treatment, highlighting its role in both intestinal and neurological inflammatory processes.